Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 56 | 2024 | 5097 | 3.350 |
Why?
|
| Pre-Exposure Prophylaxis | 11 | 2024 | 196 | 3.210 |
Why?
|
| Sexual Behavior | 29 | 2023 | 320 | 2.290 |
Why?
|
| Adolescent | 59 | 2024 | 2985 | 1.910 |
Why?
|
| Young Adult | 46 | 2024 | 2498 | 1.650 |
Why?
|
| South Africa | 69 | 2024 | 7596 | 1.570 |
Why?
|
| Female | 67 | 2024 | 9103 | 1.540 |
Why?
|
| Male | 55 | 2024 | 6754 | 1.480 |
Why?
|
| Humans | 74 | 2024 | 14537 | 1.390 |
Why?
|
| Cell Phone | 3 | 2020 | 34 | 1.320 |
Why?
|
| Condoms | 9 | 2020 | 88 | 1.180 |
Why?
|
| Adult | 37 | 2024 | 5913 | 1.110 |
Why?
|
| Anti-HIV Agents | 9 | 2024 | 1324 | 1.100 |
Why?
|
| AIDS Vaccines | 4 | 2022 | 152 | 1.050 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 1422 | 0.950 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2024 | 256 | 0.950 |
Why?
|
| Biomedical Research | 3 | 2022 | 49 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 11 | 2024 | 262 | 0.830 |
Why?
|
| Depression | 4 | 2021 | 121 | 0.810 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 34 | 0.790 |
Why?
|
| Adolescent Health Services | 4 | 2018 | 17 | 0.700 |
Why?
|
| Personal Autonomy | 1 | 2021 | 6 | 0.690 |
Why?
|
| Pediatrics | 1 | 2021 | 17 | 0.680 |
Why?
|
| Cell Phone Use | 1 | 2021 | 6 | 0.670 |
Why?
|
| Safe Sex | 6 | 2019 | 68 | 0.670 |
Why?
|
| Surveys and Questionnaires | 13 | 2024 | 563 | 0.650 |
Why?
|
| Reminder Systems | 1 | 2020 | 8 | 0.640 |
Why?
|
| Vaginosis, Bacterial | 5 | 2020 | 19 | 0.620 |
Why?
|
| Reproductive Health Services | 2 | 2018 | 66 | 0.610 |
Why?
|
| Intimate Partner Violence | 4 | 2023 | 55 | 0.570 |
Why?
|
| Counselors | 1 | 2018 | 6 | 0.550 |
Why?
|
| Substance-Related Disorders | 7 | 2021 | 51 | 0.540 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 106 | 0.540 |
Why?
|
| Qualitative Research | 7 | 2024 | 321 | 0.530 |
Why?
|
| Risk-Taking | 7 | 2022 | 121 | 0.530 |
Why?
|
| Sexually Transmitted Diseases | 7 | 2020 | 103 | 0.520 |
Why?
|
| Adolescent Behavior | 7 | 2018 | 60 | 0.520 |
Why?
|
| Mental Health | 5 | 2023 | 91 | 0.510 |
Why?
|
| Sexual Partners | 8 | 2023 | 215 | 0.480 |
Why?
|
| Circumcision, Male | 4 | 2020 | 99 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 4 | 2020 | 125 | 0.460 |
Why?
|
| Zimbabwe | 4 | 2023 | 120 | 0.460 |
Why?
|
| Uganda | 4 | 2023 | 197 | 0.460 |
Why?
|
| Papillomavirus Infections | 3 | 2021 | 74 | 0.440 |
Why?
|
| Self Report | 3 | 2020 | 114 | 0.430 |
Why?
|
| Self Efficacy | 4 | 2018 | 11 | 0.430 |
Why?
|
| Vagina | 3 | 2019 | 91 | 0.420 |
Why?
|
| Cohort Studies | 7 | 2022 | 967 | 0.410 |
Why?
|
| Papillomavirus Vaccines | 3 | 2020 | 18 | 0.400 |
Why?
|
| Reproductive Health | 3 | 2021 | 51 | 0.370 |
Why?
|
| Focus Groups | 5 | 2020 | 196 | 0.350 |
Why?
|
| Heterosexuality | 3 | 2021 | 30 | 0.340 |
Why?
|
| Noncommunicable Diseases | 3 | 2020 | 77 | 0.330 |
Why?
|
| Vaginal Smears | 2 | 2021 | 34 | 0.320 |
Why?
|
| Attitude to Health | 3 | 2021 | 56 | 0.310 |
Why?
|
| Parent-Child Relations | 3 | 2014 | 16 | 0.300 |
Why?
|
| Risk Assessment | 3 | 2020 | 225 | 0.300 |
Why?
|
| Middle Aged | 7 | 2024 | 3601 | 0.300 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2021 | 115 | 0.300 |
Why?
|
| Prevalence | 8 | 2021 | 1192 | 0.300 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 26 | 0.290 |
Why?
|
| Epidemics | 2 | 2021 | 65 | 0.290 |
Why?
|
| HIV | 2 | 2022 | 380 | 0.280 |
Why?
|
| Social Stigma | 5 | 2020 | 80 | 0.280 |
Why?
|
| HIV-1 | 4 | 2019 | 1260 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 3 | 2022 | 551 | 0.270 |
Why?
|
| Prospective Studies | 6 | 2020 | 1160 | 0.270 |
Why?
|
| Violence | 3 | 2017 | 68 | 0.260 |
Why?
|
| Sexual and Gender Minorities | 2 | 2024 | 29 | 0.250 |
Why?
|
| Homosexuality, Male | 2 | 2024 | 52 | 0.250 |
Why?
|
| Income | 2 | 2024 | 85 | 0.250 |
Why?
|
| Mass Screening | 4 | 2020 | 245 | 0.240 |
Why?
|
| Social Support | 3 | 2022 | 77 | 0.240 |
Why?
|
| Sex Offenses | 3 | 2022 | 29 | 0.240 |
Why?
|
| Child | 6 | 2022 | 2242 | 0.230 |
Why?
|
| Counseling | 4 | 2020 | 143 | 0.230 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 39 | 0.210 |
Why?
|
| Transgender Persons | 1 | 2024 | 24 | 0.210 |
Why?
|
| Sex Education | 2 | 2015 | 17 | 0.210 |
Why?
|
| Homosexuality, Female | 1 | 2023 | 2 | 0.210 |
Why?
|
| Southeastern United States | 1 | 2023 | 1 | 0.210 |
Why?
|
| Prevotella | 2 | 2020 | 2 | 0.200 |
Why?
|
| Students | 1 | 2023 | 50 | 0.200 |
Why?
|
| Chlamydia Infections | 2 | 2020 | 17 | 0.200 |
Why?
|
| Communication | 3 | 2023 | 57 | 0.200 |
Why?
|
| Gonorrhea | 2 | 2020 | 20 | 0.200 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.190 |
Why?
|
| Community Participation | 1 | 2022 | 42 | 0.190 |
Why?
|
| Logistic Models | 6 | 2021 | 254 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 12 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 151 | 0.180 |
Why?
|
| Pregnancy | 7 | 2022 | 1862 | 0.180 |
Why?
|
| Sex Factors | 6 | 2019 | 227 | 0.170 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 29 | 0.170 |
Why?
|
| Unsafe Sex | 2 | 2019 | 46 | 0.170 |
Why?
|
| HIV Seropositivity | 2 | 2021 | 265 | 0.170 |
Why?
|
| Mothers | 1 | 2022 | 195 | 0.170 |
Why?
|
| Asymptomatic Infections | 2 | 2018 | 34 | 0.170 |
Why?
|
| Risk Factors | 6 | 2023 | 1475 | 0.170 |
Why?
|
| Interpersonal Relations | 4 | 2023 | 43 | 0.170 |
Why?
|
| Infant, Newborn | 2 | 2022 | 1479 | 0.160 |
Why?
|
| Gardnerella vaginalis | 1 | 2020 | 1 | 0.160 |
Why?
|
| Bacteroidaceae Infections | 1 | 2020 | 1 | 0.160 |
Why?
|
| Pregnancy in Adolescence | 1 | 2020 | 15 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 3 | 0.160 |
Why?
|
| Emtricitabine | 1 | 2020 | 78 | 0.160 |
Why?
|
| Lactobacillus | 1 | 2020 | 7 | 0.160 |
Why?
|
| Contraception Behavior | 1 | 2020 | 54 | 0.160 |
Why?
|
| Family Planning Services | 1 | 2020 | 46 | 0.160 |
Why?
|
| Text Messaging | 1 | 2020 | 25 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 43 | 0.160 |
Why?
|
| Interviews as Topic | 4 | 2024 | 203 | 0.160 |
Why?
|
| Langerhans Cells | 1 | 2019 | 3 | 0.160 |
Why?
|
| Chemokine CCL27 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2020 | 48 | 0.160 |
Why?
|
| Foreskin | 1 | 2019 | 12 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2020 | 44 | 0.150 |
Why?
|
| Tenofovir | 1 | 2020 | 171 | 0.150 |
Why?
|
| Virion | 1 | 2019 | 12 | 0.150 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 2 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 11 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2019 | 54 | 0.150 |
Why?
|
| Women's Health | 1 | 2019 | 41 | 0.150 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 411 | 0.150 |
Why?
|
| Microbiota | 1 | 2019 | 30 | 0.140 |
Why?
|
| Reproductive Tract Infections | 1 | 2018 | 8 | 0.140 |
Why?
|
| Interleukin-1alpha | 1 | 2018 | 1 | 0.140 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Dysbiosis | 1 | 2018 | 2 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 9 | 0.140 |
Why?
|
| Negotiating | 1 | 2018 | 8 | 0.140 |
Why?
|
| Alphapapillomavirus | 1 | 2018 | 8 | 0.140 |
Why?
|
| Data Collection | 1 | 2018 | 86 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 280 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 293 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2018 | 101 | 0.130 |
Why?
|
| Pandemics | 3 | 2024 | 296 | 0.130 |
Why?
|
| HIV Seronegativity | 1 | 2017 | 52 | 0.130 |
Why?
|
| Aged | 1 | 2022 | 1740 | 0.130 |
Why?
|
| Homosexuality | 2 | 2014 | 5 | 0.130 |
Why?
|
| Caregivers | 2 | 2013 | 76 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 55 | 0.120 |
Why?
|
| Perception | 3 | 2020 | 42 | 0.110 |
Why?
|
| Treatment Refusal | 1 | 2015 | 13 | 0.110 |
Why?
|
| Disclosure | 1 | 2015 | 25 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2015 | 15 | 0.110 |
Why?
|
| Behavior, Addictive | 1 | 2014 | 2 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 152 | 0.100 |
Why?
|
| Bisexuality | 1 | 2013 | 3 | 0.100 |
Why?
|
| Gender Identity | 2 | 2023 | 23 | 0.100 |
Why?
|
| Family Characteristics | 3 | 2021 | 135 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2015 | 240 | 0.100 |
Why?
|
| Parents | 1 | 2013 | 32 | 0.090 |
Why?
|
| Patient Participation | 1 | 2011 | 13 | 0.090 |
Why?
|
| Africa, Southern | 2 | 2022 | 91 | 0.080 |
Why?
|
| Stereotyping | 1 | 2009 | 5 | 0.070 |
Why?
|
| Fertility | 1 | 2009 | 22 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2019 | 63 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 435 | 0.070 |
Why?
|
| Cytokines | 2 | 2019 | 107 | 0.070 |
Why?
|
| Age Factors | 2 | 2020 | 370 | 0.070 |
Why?
|
| Decision Making | 2 | 2018 | 53 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2020 | 472 | 0.060 |
Why?
|
| Viral Load | 2 | 2019 | 819 | 0.050 |
Why?
|
| Food Assistance | 1 | 2024 | 2 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 29 | 0.050 |
Why?
|
| Quarantine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Sexuality | 1 | 2022 | 11 | 0.050 |
Why?
|
| Men | 1 | 2022 | 15 | 0.050 |
Why?
|
| Work | 1 | 2020 | 9 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 23 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 127 | 0.040 |
Why?
|
| Social Environment | 1 | 2020 | 11 | 0.040 |
Why?
|
| Clindamycin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 106 | 0.040 |
Why?
|
| Metronidazole | 1 | 2020 | 4 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 11 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2020 | 13 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 49 | 0.040 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2020 | 15 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 34 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 163 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 59 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 13 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 11 | 0.040 |
Why?
|
| Contraception | 1 | 2020 | 90 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 89 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Psychometrics | 1 | 2019 | 22 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 107 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 96 | 0.040 |
Why?
|
| Glycogen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 135 | 0.040 |
Why?
|
| Public Sector | 1 | 2020 | 82 | 0.040 |
Why?
|
| Coitus | 1 | 2019 | 15 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 151 | 0.040 |
Why?
|
| Lactobacillus crispatus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 5 | 0.040 |
Why?
|
| Estrogens | 1 | 2019 | 6 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2019 | 22 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 188 | 0.040 |
Why?
|
| Urban Population | 1 | 2021 | 257 | 0.040 |
Why?
|
| Overweight | 1 | 2019 | 87 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Trichomonas Infections | 1 | 2018 | 5 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2018 | 7 | 0.040 |
Why?
|
| Syphilis | 1 | 2018 | 14 | 0.040 |
Why?
|
| Candidiasis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Bodily Secretions | 1 | 2018 | 1 | 0.040 |
Why?
|
| Gardnerella | 1 | 2018 | 1 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 7 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 167 | 0.030 |
Why?
|
| Exposure to Violence | 1 | 2018 | 2 | 0.030 |
Why?
|
| Child Abuse | 1 | 2018 | 10 | 0.030 |
Why?
|
| Domestic Violence | 1 | 2018 | 8 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 321 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 150 | 0.030 |
Why?
|
| Kenya | 1 | 2018 | 183 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2017 | 20 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 104 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 91 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 260 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 217 | 0.030 |
Why?
|
| Primates | 1 | 2017 | 2 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 327 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 353 | 0.030 |
Why?
|
| Obesity | 1 | 2019 | 367 | 0.030 |
Why?
|
| Psychology | 1 | 2016 | 4 | 0.030 |
Why?
|
| Social Determinants of Health | 1 | 2016 | 11 | 0.030 |
Why?
|
| Urban Health | 1 | 2016 | 78 | 0.030 |
Why?
|
| Social Isolation | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2020 | 543 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 62 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 1081 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 171 | 0.030 |
Why?
|
| Harm Reduction | 1 | 2013 | 7 | 0.030 |
Why?
|
| Health Communication | 1 | 2013 | 3 | 0.020 |
Why?
|
| Peer Group | 1 | 2013 | 14 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2015 | 656 | 0.020 |
Why?
|
| Africa | 1 | 2013 | 376 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 799 | 0.020 |
Why?
|
| Life Change Events | 1 | 2011 | 9 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 112 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 57 | 0.020 |
Why?
|